Breaking Finance News

TheStreet downgraded Lannett Company, Inc. (NYSE:LCI) to Hold in a report released today.

TheStreet has downgraded Lannett Company, Inc. (NYSE:LCI) to Hold in a report released on 10/18/2016.

Yesterday Lannett Company, Inc. (NYSE:LCI) traded -1.09% lower at $22.60. The company’s 50-day moving average is $29.08 and its 200-day moving average is $25.99. The last closing price is down -13.04% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. 1,053,792 shares of the stock traded hands, up from an average trading volume of 1,022,580

See Chart Below

Lannett Company, Inc. (NYSE:LCI)

Lannett Company, Inc. has a 52 week low of $16.91 and a 52 week high of $49.44 with a P/E ratio of 18.83 The company’s market cap is currently $0.

In addition to TheStreet reporting its stock price target, a total of 4 brokers have issued a report on the company. The average stock price target is $29.13 with 0 brokers rating the stock a strong buy, 4 brokers rating the stock a buy, 1 broker rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Lannett Company, Inc. (NYSE:LCI)

Lannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. As of June 30, 2016, the Company's products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules. The Company has additional products under development, which are orally administered solid oral-dosage products (tablet/capsule) or oral solutions, nasal, topicals or parentarels, as well as other dosage forms.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.